The development of PD-1-targeting ICB treatments for cancer patients was sparked by evidence from the aforementioned and similar research showing blocking the PD-1 pathway can improve tumor immune control and anti-tumor T cell reactivity. The gene discussed is PDCD1; the disease is neoplasm.